Human immunodeficiency virus seroprevalence among blood product recipients in San Francisco before transfusion.
Human immunodeficiency virus seroprevalence among blood product recipients in San Francisco before transfusion.
复制标题
旧金山血液制品接受者输血前人类免疫缺陷病毒血清阳性率。
DOI：
10.1046/j.1537-2995.1989.29289146827.x
复制
发表时间：
1989
期刊：
影响因子：
2.9
通讯作者：
Vyas,GN
中科院分区：
文献类型：
--
作者：
Hwang,LY;Beasley,RP;Busch,MP;Lane,PK;Vyas,GN
为了确定捐献血液常规筛查后输血相关人类免疫缺陷病毒（HIV）感染的发生率，一项初步研究估计了旧金山弗朗西斯科血液制品接受者输血前HIV感染的患病率。在来自没有获得性免疫缺陷综合征（AIDS）或艾滋病相关综合征（ARC）临床病史的受者的911份非重复输血前标本中，HIV抗体的总体患病率为2.9%（男性为5.2%，女性为0.6%; p = 0.00002）。如果排除特定定义或可能的高风险组（n = 348）中的受体，则检测到1.8%（10/563）的血清阳性率，所有阳性发生在男性（10/242，4.1%）中，女性（0/321，0%）中无阳性。这表明，在旧金山弗朗西斯科的血液制品接受者中，输血前艾滋病毒感染的流行率大大高于献血者人群中已知的0.02%至0.04%的流行率。因此，对于目前接受血清反应阴性输血的患者而言，没有已知艾滋病风险的妇女人群是评估艾滋病毒感染风险的最佳人群。
To determine the incidence of transfusion‐associated human immunodeficiency virus (HIV) infection after routine screening of donated blood, a pilot study estimated the pretransfusion prevalence of HIV infection among blood product recipients in San Francisco. Among the 911 nonduplicate pretransfusion specimens from recipients without a clinical history of acquired immune deficiency syndrome (AIDS) or AIDS‐related complex (ARC), the overall prevalence of antibody to HIV was 2.9 percent (5.2% among males and 0.6% among females; p = 0.00002). If recipients in specifically defined or possible high‐risk groups (n = 348) were excluded, a seropositivity rate of 1.8 percent (10/563) was detected, with all the positives occurring in men (10/242, 4.1%) and none in women (0/321, 0%). This demonstrated prevalence of HIV infection among blood product recipients in San Francisco before transfusion was substantially higher than the known 0.02 to 0.04 percent prevalence in the donor population. Therefore, the population of women without known risk for AIDS is the best in which to assess the risk of HIV infection in patients who are currently receiving seronegative blood transfusions.